Quale sarebbe il prezzo per Walvax Biotechnology Co., Ltd. (300142)

Il prezzo per Walvax Biotechnology Co., Ltd. (300142) è $2.21

Qual è la capitalizzazione di mercato per Walvax Biotechnology Co., Ltd. (300142)

La capitalizzazione di mercato per Walvax Biotechnology Co., Ltd. (300142) è $3.54B

Walvax Biotechnology Co., Ltd. (300142) Dividendi

Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.

Anno	Dividendo (rettificato per split azionari)	Cambia
Non abbastanza dati per le date fornite.

Anno

Dividendo (rettificato per split azionari)

Cambia

Non abbastanza dati per le date fornite.

Anno	Dividendo	Cambia
Non abbastanza dati per le date fornite.

Anno

Dividendo

Cambia

Non abbastanza dati per le date fornite.

Azienda	Numero di pagamenti di dividendi	Il paese
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	DE
Merck KGaA MRK.DE	0.00%	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	JP
Galderma Group AG GALD.SW	0.00%	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	38.00%	IN

Azienda

Numero di pagamenti di dividendi

Il paese